South Korea’s MFDS approved Curocell’s Rimqarto (anbal-cel), positioning it as the first homegrown CAR T-cell therapy for advanced diffuse large B-cell lymphoma. The approval marks a manufacturing and clinical capability milestone for domestic development within the competitive CAR T landscape. With Rimqarto cleared for a defined lymphoma setting, Curocell’s near-term focus shifts to scaling access, maintaining manufacturing consistency, and supporting real-world outcomes that can influence future label expansions.